Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04420975 | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | active not recruiting | Phase 1 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04454528 | BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy(BreastVAX) | active not recruiting | Phase 1 / Phase 2 | 27 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 10, 2026 |
| clinicaltrials |
| NCT05781048 | A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 56 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04020809 | Neoadjuvant Atezolizumab in Cutaneous Melanoma | active not recruiting | Phase 1 | 20 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05229497 | A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors | active not recruiting | Phase 1 / Phase 2 | 154 | AkesoINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05573555 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) | active not recruiting | Phase 1 / Phase 2 | 20 | PfizerINDUSTRY | 4 | Mar 9, 2026 | clinicaltrials |
| NCT05660408 | RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors(RNA PRIME) | active not recruiting | Phase 1 / Phase 2 | 36 | University of FloridaOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05707910 | Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors | active not recruiting | Phase 1 | 6 | West China HospitalOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05904379 | AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 233 | AkesoINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06646055 | AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 110 | AkesoINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05103631 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | active not recruiting | Phase 1 | 12 | Baylor College of MedicineOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05540340 | A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant | active not recruiting | Phase 1 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT01970722 | Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer | active not recruiting | Phase 1 | 40 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03260491 | U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 312 | Daiichi SankyoINDUSTRY | 6 | Mar 5, 2026 | clinicaltrials |
| NCT04094961 | Ixazomib + Pomalidomide + Dexamethasone In MM | active not recruiting | Phase 1 / Phase 2 | 52 | Omar Nadeem, MDOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04661384 | Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | active not recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05122546 | CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | active not recruiting | Phase 1 | 31 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05166616 | Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 8 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05290597 | A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas | active not recruiting | Phase 1 | 40 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06883630 | A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC | active not recruiting | Phase 1 | 121 | RemeGen Co., Ltd.INDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06961786 | TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma(TUNINTIL-2) | active not recruiting | Phase 1 | 9 | TILT Biotherapeutics Ltd.INDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03070327 | BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma | active not recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03152318 | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2(rQNestin) | active not recruiting | Phase 1 | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03223155 | Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer(COSINR) | active not recruiting | Phase 1 | 78 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03741127 | Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 | active not recruiting | Phase 1 | 100 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03844815 | Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia | active not recruiting | Phase 1 | 26 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05846867 | A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 170 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05078866 | Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients | active not recruiting | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 2 | Mar 3, 2026 | clinicaltrials |
| NCT05546268 | Study of Oral MRT-2359 in Selected Cancer Patients | active not recruiting | Phase 1 / Phase 2 | 174 | Monte Rosa Therapeutics, IncINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT02721459 | XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma | active not recruiting | Phase 1 | 26 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06715124 | QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations | active not recruiting | Phase 1 | 237 | Quanta TherapeuticsINDUSTRY | 1 | Mar 2, 2026 | clinicaltrials |
| NCT01684397 | Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer | active not recruiting | Phase 1 / Phase 2 | 51 | Roswell Park Cancer InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03272334 | Her2-BATS and Pembrolizumab in Metastatic Breast Cancer(Breast-47) | active not recruiting | Phase 1 / Phase 2 | 22 | University of VirginiaOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03434769 | AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma | active not recruiting | Phase 1 | 31 | Benjamin TomlinsonOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03833700 | A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) | active not recruiting | Phase 1 | 70 | Eisai Co., Ltd.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04270149 | Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer | active not recruiting | Phase 1 | 8 | Herbert LyerlyOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04294628 | Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer | active not recruiting | Phase 1 | 62 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04336241 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | active not recruiting | Phase 1 | 36 | Replimune, Inc.INDUSTRY | 2 | Feb 27, 2026 | clinicaltrials |
| NCT04735978 | Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours | active not recruiting | Phase 1 | 123 | Replimune, Inc.INDUSTRY | 5 | Feb 27, 2026 | clinicaltrials |
| NCT04943536 | Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer(BiolenRT) | active not recruiting | Phase 1 | 20 | Alessa Therapeutics Inc.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05869539 | ACT-TIL and ANV419 for Advanced Melanoma.(BaseTIL-03M) | active not recruiting | Phase 1 | 10 | University Hospital, Basel, SwitzerlandOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05914376 | Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors | active not recruiting | Phase 1 | 24 | Hangzhou Converd Co., Ltd.INDUSTRY | 1 | Feb 27, 2026 | clinicaltrials |
| NCT02716116 | A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 334 | TakedaINDUSTRY | 10 | Feb 25, 2026 | clinicaltrials |
| NCT03974217 | Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts | active not recruiting | Phase 1 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04764942 | Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial | active not recruiting | Phase 1 / Phase 2 | 39 | Mayo ClinicOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT05261750 | Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer | active not recruiting | Phase 1 / Phase 2 | 15 | PT. Prodia Stem Cell IndonesiaINDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT05642962 | Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) | active not recruiting | Phase 1 / Phase 2 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06052813 | A Study of BN104 in the Treatment of Acute Leukemia | active not recruiting | Phase 1 / Phase 2 | 66 | Institut de Recherches Internationales Servier (I.R.I.S.)INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT00378105 | Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 68 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04471727 | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | active not recruiting | Phase 1 / Phase 2 | 232 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 10, 2026source: clinicaltrials